The One Ecolab initiative has delivered $25 million of cumulative cost savings with estimated annualized cost savings of $140 million in continuing operations by 2027. This initiative aims to enhance growth and margin expansion.

Organic sales for Global Life Sciences increased 5% driven by new business wins and improving industry trends. This segment is becoming a more significant contributor to overall growth.

The sale of the global surgical solutions business negatively impacted reported net sales. This divestiture is part of a strategic portfolio optimization.

Selling, general and administrative (SG&A) expenses as a percentage of sales decreased to 28.4% from 28.7% in the prior year. This indicates improved operational efficiency and cost control.

The company is incurring restructuring costs related to the 'One Ecolab' initiative, with $39.4 million recorded in the current quarter. This reflects management's efforts to streamline operations, but also highlights short-term expenses.

The reported tax rate was 20.3%, significantly higher than the 9.2% in the prior year, due to discrete tax items and special charges. This makes it difficult to assess the underlying tax efficiency.

The company acknowledges that international operations are subject to changes in economic conditions and foreign currency exchange rates, as well as political uncertainty. This highlights the vulnerability to macroeconomic factors.

The company is involved in litigation stemming from the TPC Group plant explosion, with potential insurance coverage. The outcome is uncertain and could lead to future litigation.

The Company was recently named in a lawsuit arising out of a vehicle collision in which the plaintiffs seek monetary damages. The Company believes any potential loss should be covered by insurance subject to its deductible. Due to the early stage of the litigation, an estimate of any loss or range of losses cannot be made at this time.

Adjusted gross margin increased when comparing the first quarter of 2025 against the first quarter of 2024 reflecting strong value pricing. This indicates the company's ability to maintain or increase prices despite competitive pressures.

While Global Water and Global Life Sciences showed growth, the performance of other segments varied, indicating differing competitive dynamics across different business areas.

Fixed currency sales increased 7%, reflecting a benefit from attractive, targeted acquisitions in North America. This shows the company is actively expanding its reach and capabilities through strategic acquisitions.

Adjusted gross margin increased when comparing the first quarter of 2025 against the first quarter of 2024 reflecting strong value pricing. This suggests improvements in cost management or pricing strategies.

Selling, general and administrative (SG&A) expenses as a percentage of sales decreased to 28.4% from 28.7% in the prior year. This indicates improved operational efficiency and cost control.

The One Ecolab initiative has delivered $25 million of cumulative cost savings with estimated annualized cost savings of $140 million in continuing operations by 2027. This initiative aims to enhance growth and margin expansion.

As a program within this initiative, we also announced that we commenced a restructuring plan to leverage our digital technologies to realign the functional work done in many countries into global centers of excellence.

Light & Heavy organic sales increased 3% in the first quarter of 2025 driven by accelerating growth in high tech and solid growth in manufacturing and downstream which more than offset slightly lower sales in basic industries. High tech reported strong double-digit sales growth driven by cooling technologies for data centers and circular water for microelectronics.

Our increasing reliance on artificial intelligence technologies in our products, services and operations.

The company reacquired $154 million of shares in the first quarter of 2025. This reflects a continued commitment to returning capital to shareholders.

The company paid dividends of $192 million in the first three months of 2025. This indicates a stable capital allocation policy.

Total capital expenditures were $238 million and $202 million in the first quarter of 2025 and 2024, respectively. This shows the company is actively investing in its business.

The costs and effects of complying with laws and regulations, including those relating to the environment, climate change standards, and to the manufacture, storage, distribution, sale and use of our products, as well as to the conduct of our business generally, including labor and employment and anti-corruption; potential chemical spill or release; our commitments, goals, targets, objectives and initiatives related to sustainability

The company acknowledges that international operations are subject to changes in economic conditions and foreign currency exchange rates, as well as political uncertainty. This highlights the vulnerability to macroeconomic factors.

Reported GAAP net sales decreased by 2% to $3,695.0 million driven by an unfavorable impact from the sale of the global surgical solutions business and currency translation. This highlights the sensitivity to currency fluctuations.

Argentina, Turkey and Egypt are classified as highly inflationary economies in accordance with U.S. GAAP, and the U.S. dollar is the functional currency for our subsidiaries in Argentina, Turkey and Egypt.